Novo Nordisk's CagriSema Drug Trial Data Falls Short Again Shares Plunge by 8 Percent US$ 29.29 Min. order: 1 piece ★★★★★ 4.2 (22 reviews) Sold : Login>>
Novo Nordisk's Cagrilintide shows promising weight loss in REDEFINE-1 sub-analysis, unveiled at EASD 2025 US$ 25.51 Min. order: 1 piece ★★★★★ 4.8 (154 reviews) Sold : Login>>
Novo's Amylin Injectable Cagrilintide Hits 11.8% Weight Reduction in Phase III Trial US$ 29.19 Min. order: 1 piece ★★★★★ 4.6 (41 reviews) Sold : Login>>
Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management US$ 27.43 Min. order: 1 piece ★★★★★ 4.9 (181 reviews) Sold : Login>>
Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had ≥1 weight-related complication, individuals assigned to a combination US$ 27.88 Min. order: 1 piece ★★★★★ 4.9 (120 reviews) Sold : Login>>
Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had ≥1 weight-related complication, individuals assigned to a combination US$ 25.26 Min. order: 1 piece ★★★★★ 4.2 (174 reviews) Sold : Login>>